Tags

Type your tag names separated by a space and hit enter

The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
J Diabetes Complications. 2006 Nov-Dec; 20(6):343-8.JD

Abstract

OBJECTIVES

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a novel inflammation marker. We investigated its association with other coronary risk factors and evaluated its role as a comprehensive marker of the metabolic syndrome in individuals with type 2 diabetes.

METHODS

Our cross-sectional study evaluated 92 insulin-treated subjects with type 2 diabetes. Biochemical measurements of Lp-PLA(2), glycemic control, lipid profiles, and C-reactive protein were carried out. Seventy-seven subjects were diagnosed as having the metabolic syndrome, which was defined according to the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

RESULTS

Lp-PLA(2) was significantly correlated with waist-hip ratio (r=.25), triglycerides (r=.50), high-density lipoprotein cholesterol (r=-.31), and low-density lipoprotein cholesterol (LDL-C; r=.27; all P<.02). In a multiple-regression model, triglycerides and LDL-C levels were the significant predictors of Lp-PLA(2). Lp-PLA(2) was significantly higher in subjects with the metabolic syndrome than in those without it (268+/-23.4 vs. 127+/-15.8 ng/ml, P<.001). There was a linear increase in Lp-PLA(2) with an increment of the number of the metabolic syndrome criteria (P(trend)=.041). Another multiple-regression model showed that the hypertriglyceridemia component was the only predictor of Lp-PLA(2).

CONCLUSIONS

Our findings suggest that Lp-PLA(2) assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin.

Authors+Show Affiliations

The University Diabetes Treatment Center, Parkland Memorial Hospital, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8858, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17070436

Citation

Noto, Hiroshi, et al. "The Role of Lipoprotein-associated Phospholipase A(2) in the Metabolic Syndrome and Diabetes." Journal of Diabetes and Its Complications, vol. 20, no. 6, 2006, pp. 343-8.
Noto H, Chitkara P, Raskin P. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. J Diabetes Complications. 2006;20(6):343-8.
Noto, H., Chitkara, P., & Raskin, P. (2006). The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. Journal of Diabetes and Its Complications, 20(6), 343-8.
Noto H, Chitkara P, Raskin P. The Role of Lipoprotein-associated Phospholipase A(2) in the Metabolic Syndrome and Diabetes. J Diabetes Complications. 2006 Nov-Dec;20(6):343-8. PubMed PMID: 17070436.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes. AU - Noto,Hiroshi, AU - Chitkara,Pranav, AU - Raskin,Philip, PY - 2006/06/06/received PY - 2006/07/07/accepted PY - 2006/10/31/pubmed PY - 2007/2/17/medline PY - 2006/10/31/entrez SP - 343 EP - 8 JF - Journal of diabetes and its complications JO - J Diabetes Complications VL - 20 IS - 6 N2 - OBJECTIVES: Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a novel inflammation marker. We investigated its association with other coronary risk factors and evaluated its role as a comprehensive marker of the metabolic syndrome in individuals with type 2 diabetes. METHODS: Our cross-sectional study evaluated 92 insulin-treated subjects with type 2 diabetes. Biochemical measurements of Lp-PLA(2), glycemic control, lipid profiles, and C-reactive protein were carried out. Seventy-seven subjects were diagnosed as having the metabolic syndrome, which was defined according to the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. RESULTS: Lp-PLA(2) was significantly correlated with waist-hip ratio (r=.25), triglycerides (r=.50), high-density lipoprotein cholesterol (r=-.31), and low-density lipoprotein cholesterol (LDL-C; r=.27; all P<.02). In a multiple-regression model, triglycerides and LDL-C levels were the significant predictors of Lp-PLA(2). Lp-PLA(2) was significantly higher in subjects with the metabolic syndrome than in those without it (268+/-23.4 vs. 127+/-15.8 ng/ml, P<.001). There was a linear increase in Lp-PLA(2) with an increment of the number of the metabolic syndrome criteria (P(trend)=.041). Another multiple-regression model showed that the hypertriglyceridemia component was the only predictor of Lp-PLA(2). CONCLUSIONS: Our findings suggest that Lp-PLA(2) assay potentially facilitates a more comprehensive assessment of the metabolic syndrome in patients with type 2 diabetes on insulin. SN - 1056-8727 UR - https://www.unboundmedicine.com/medline/citation/17070436/The_role_of_lipoprotein_associated_phospholipase_A_2__in_the_metabolic_syndrome_and_diabetes_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1056-8727(06)00075-4 DB - PRIME DP - Unbound Medicine ER -